Literature DB >> 16725222

Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein.

Tae-Hwe Heo1, Song-Mi Lee, Birke Bartosch, François-Loïc Cosset, Chang-Yuil Kang.   

Abstract

Limited information is available regarding hepatitis C virus (HCV) entry events. Viral attachment and infection studies have been performed using HCV envelope glycoprotein (E2) and HCV pseudo-particle (HCVpp) models to obtain general information about the early entry events. However, the details involved in each step of viral entry into human cells are still obscure. This study provides molecular clue for the formation of a heteromultimeric complex as a possible post-attachment step. Among several putative receptors, human CD81 and scavenger receptor class B type 1 (SR-B1) have been demonstrated as considerable determinants in infectious outcome as well as attachment. In this study, we provide molecular evidence demonstrating that HCV E2 links soluble CD81 and SR-B1 protein together. This physical neighboring might explain why both CD81 and SR-B1 are indispensable factors for HCVpp infection. These data further elucidate our understanding of HCV entry and provide new insight into directing future studies identifying novel liver-specific fusion receptor(s).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16725222     DOI: 10.1016/j.virusres.2006.04.002

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  8 in total

1.  Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion.

Authors:  Nishi R Sharma; Guaniri Mateu; Marlene Dreux; Arash Grakoui; François-Loïc Cosset; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

2.  High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.

Authors:  Maria Teresa Catanese; Rita Graziani; Thomas von Hahn; Martine Moreau; Thierry Huby; Giacomo Paonessa; Claudia Santini; Alessandra Luzzago; Charles M Rice; Riccardo Cortese; Alessandra Vitelli; Alfredo Nicosia
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

3.  Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I.

Authors:  Sharookh B Kapadia; Heidi Barth; Thomas Baumert; Jane A McKeating; Francis V Chisari
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

4.  The HCV Envelope Glycoprotein Down-Modulates NF-κB Signalling and Associates With Stimulation of the Host Endoplasmic Reticulum Stress Pathway.

Authors:  Lindsay G A McKay; Jordan Thomas; Wejdan Albalawi; Antoine Fattaccioli; Marc Dieu; Alessandra Ruggiero; Jane A McKeating; Jonathan K Ball; Alexander W Tarr; Patricia Renard; Georgios Pollakis; William A Paxton
Journal:  Front Immunol       Date:  2022-03-15       Impact factor: 7.561

5.  Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.

Authors:  Marlène Dreux; Viet Loan Dao Thi; Judith Fresquet; Maryse Guérin; Zélie Julia; Géraldine Verney; David Durantel; Fabien Zoulim; Dimitri Lavillette; François-Loïc Cosset; Birke Bartosch
Journal:  PLoS Pathog       Date:  2009-02-20       Impact factor: 6.823

Review 6.  Hepatitis C Virus entry: the early steps in the viral replication cycle.

Authors:  Ali Sabahi
Journal:  Virol J       Date:  2009-07-30       Impact factor: 4.099

7.  Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.

Authors:  Katharina B Rothwangl; Balaji Manicassamy; Susan L Uprichard; Lijun Rong
Journal:  Virol J       Date:  2008-03-20       Impact factor: 4.099

8.  Identification of scavenger receptor B1 as the airway microfold cell receptor for Mycobacterium tuberculosis.

Authors:  Haaris S Khan; Vidhya R Nair; Cody R Ruhl; Samuel Alvarez-Arguedas; Jorge L Galvan Rendiz; Luis H Franco; Linzhang Huang; Philip W Shaul; Jiwoong Kim; Yang Xie; Ron B Mitchell; Michael U Shiloh
Journal:  Elife       Date:  2020-03-05       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.